A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease.

Autor: Snow, Barry1,2 (AUTHOR) BSnow@adhb.govt.nz, Mulroy, Eoin1,2 (AUTHOR) EoinM@adhb.govt.nz, Bok, Arnold1,2 (AUTHOR) AriB@adhb.govt.nz, Simpson, Mark1,2 (AUTHOR) MarkS@adhb.govt.nz, Smith, Andrew3 (AUTHOR) Asmith@adhb.govt.nz, Taylor, Kenneth4 (AUTHOR) ktaylor@lctglobal.com, Lockhart, Michelle4 (AUTHOR) michellelockhart@xtra.co.nz, Lam, BB Janice4 (AUTHOR) jlam@lctglobal.com, Frampton, Christopher5 (AUTHOR) Chris.frampton@otago.ac.nz, Schweder, Patrick1,2 (AUTHOR) PatrickS@adhb.govt.nz, Chen, Benson1,2 (AUTHOR) BensonC@adhb.govt.nz, Finucane, Gregory1,2 (AUTHOR) greg@neuropsychiatry.co.nz, McMahon, Adele1,2 (AUTHOR) AdeleMcM@adhb.govt.nz, Macdonald, Lorraine1,2 (AUTHOR) LorrMacd@adhb.govt.nz
Zdroj: Parkinsonism & Related Disorders. Apr2019, Vol. 61, p88-93. 6p.
Databáze: Academic Search Ultimate
Externí odkaz: